| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H10O2 |
| Molecular Weight | 174.1959 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC(O)=C2C=CC=CC2=C1O
InChI
InChIKey=ZJTLZYDQJHKRMQ-UHFFFAOYSA-N
InChI=1S/C11H10O2/c1-7-6-10(12)8-4-2-3-5-9(8)11(7)13/h2-6,12-13H,1H3
| Molecular Formula | C11H10O2 |
| Molecular Weight | 174.1959 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Menadiol is one of the forms of vitamin K4. Chemically, it is closely related to menadione. Oral menadiol appears to be an effectiv ealternative to intravenous phytomenadione in the correction of coagulopathies associated with obstructiveliver disease. This simplifies the care of patients with deranged clotting times requiring cholangeopancrea-tography, particularly those to be managed as out-patients. Menadiol should receive clinical testing as a chemosensitizing agent in human lymphatic neoplasms (HLN). This effect occurred at a concentration (2.0 micrograms/ml; 4.7 microM) of menadiol which is probably clinically achievable and which did not deplete intracellular glutathione.
Approval Year
Doses
AEs
Sourcing
PubMed
Sample Use Guides
Adults: Usual therapeutic dose: 10-40mg daily
Children: If, on the recommendation of a physician, a children's dosage is required, it is suggested that 5-20mg daily be given.
The elderly: Recommendations for use in the elderly do not differ from those for other adults.
Route of Administration:
Oral
